(i) The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-8.... Accessed on June 5, 2009.
(ii) The International Diabetes Federation Diabetes Atlas. Available at: http://www.eatlas.idf.org/index29fc.html.... June 5, 2009.
(iii) Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281 (21):2005-2012.
(iv) The International Diabetes Federation Diabetes Atlas. Available at http://www.eatlas.idf.org/index755a.html.... Accessed on June 5, 2009.
(v) The International Diabetes Federation Diabetes Atlas. Available at http://www.eatlas.idf.org/index711b.html.... Accessed on June 5, 2009.
(vi) The International Diabetes Federation, Diabetes Atlas, 2003 Second edition. Available at: http://www.idf.org/webdata/docs/backgrou.... Accessed June 5, 9 Jun. (vii) - Kolterman, O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T, Taylor K, Kim D, Aisporna M, Wang Y, Baron A. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2003; 88(7):3082-3089.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO)
Amylin - Anne Erickson, +1-858-754-4443, Cell: +1-858-349-3195, anne.erickson@amylin.com; or Lilly - Tim Coulom, +1-317-655-2998, Cell: +1-317-554-9757, coulomtd@lilly.com. Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO; Logo: http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO
